Wikipedia

Gap junction modulator

(Redirected from Gap junction modulators)

A gap junction modulator is a compound or agent that either facilitates or inhibits the transfer of small molecules between biological cells by regulating gap junctions.[1] Various physiological processes including cardiac, neural or auditory, depend on gap junctions to perform crucial regulatory roles, and the modulators themselves are the key players in this procedure.[2][3][4][5] Gap junctions are necessary for diffusion of small molecules from cell to cell, keeping the cells interlinked and connecting the cytoplasm, allowing transfer of signals or resources between the body.[1][2]

Many different molecules act as modulators in gap junctions, from simple ions to complex proteins.[2][6][7] Protein kinases modulate the opening and closing of connexin pores by moderating phosphorylation.[6] Chemical gating modulators such as calmodulin, calcium, and pH values are key in regulating the gap junction proteins.[7][8] The functions of different modulators can be categorized into five aspects, including enhancement and inhibition of gap junctions activities; modulation of connexin; voltage specificity; and natural compounds.[2][3][9]

These modulators can be potential therapeutic targets for a number of disorders and are essential in the regulation of several physiological processes, potentially providing solutions to some diseases caused by issues in the gap junction.s[10] A variety of gap junction modulators as  pharmaceutical agents are being investigated to treat and regulate these diseases, such as amiodarone to treat heart issues such as ventricular arrhythmia, tonabersat to treat Cortical Spreading Depression, or rotigaptide and danegaptide to combat bupropion overdose.[10][11][12][13]

Gap Junctions

edit

Gap junctions are collections of intercellular channels that allow ions and other tiny molecules to move directly between cells.[1][14] These junctions are made up of a number of gap junction channels that consist of two connexons, each with six protein subunits called connexin, and a gene family of nearly 20 members encodes the connexins found in mammals[14][15]

Through gap junctions, the majority of cells in tissues communicate with one another, with the exception of a small number of terminally differentiated cells like blood and skeletal muscle cells.[16] The gap junction channels bridge the cytoplasm of the two cells, allowing ions and small molecules to pass in both directions through these channels[2][10]

Categories of Gap Junction Modulators

edit

Protein kinases

edit

Protein kinase enzymes moderate phosphorylation, the addition of phosphate groups, to the junction proteins play important roles in controlling the junction protein and their possible subunits.[6][17][18]

 
Connexin protein, modelled using pyMOL. pyMOL protein code taken from Protein Data Bank[19]

These kinases, such as PKA and PKC, phosphorylate the connexin gap junctions in the heart.[6][18][20] Phosphate group addition changes the charge and configuration of the connexin protein, opening (for PKA) and closing (for PKC) the transmembrane channel pores.[6][20] These same proteins can also undergo dephosphorylation by phosphatase enzymes, which reverses phosphorylation, reopening or reclosing the connexin pores.[6][17]

 
Calmodulin protein, modelled using pyMOL. pyMOL protein code taken from Protein Data Bank[21]

Chemical gating

edit

Calmodulin

edit

Calmodulin is a model Ca2+ sensor that is very adaptable, and its high-affinity Ca2+ binding domains are EF-hands, which is a structure optimized for binding to calcium ions.[22][23] Calmodulin is present in all eukaryotic cells, which mediates calcium-dependent signalling.[23][24] Calmodulin conformationally varies upon binding Ca2+ to form complexes with a wide range of target proteins.[22][23][24]

Intracellular Ca2+activated calmodulin (CaM) inhibits gap junction channels, which is critical for several cellular functions, such as lens transparency, heart contraction synchronization, and hearing.[3][5][24][25]

Calcium

edit

Calcium ions are a major modulator that can completely close the gap junction proteins.[7][23] Ca2+ ions binding to the amino acid side chains changes the structure of the protein, decreasing connectivity of other molecules.[22] Calcium affects not only connexin, but also Calmodulin, a transmembrane protein present in all eukaryotic cells.[7][22] Calcium ions are fairly abundant in cells, as they are the main signal ion of the nervous system, where the calcium released by the nervous signals can inform the junction of proteins of changes needed to adapt to their surroundings.[4][23] Ca2+ itself is associated with cell-to-cell uncoupling, which breaks apart the pathway between cells when the pathway itself becomes harmful, such as pathways to injured cells, as the abnormal pathways and communication between injured cells can cause various disorders.[7][22][25]

pH changes

edit

Changes in the pH of the environment to a more acidic or alkaline one can also affect the gap junction protein structure, changing their shape, which closes the diffusion pathways.[8][19] These pH changes are caused by chemical reactions from other metabolic processes or even inflammation signals from disease or the body's immune system.[7][19] Significant pH changes are acidification, the addition of hydrogen ions, and alkalinization, the removal of hydrogen ions.[26] Higher pH is associated with the closing of the gap junction channels, either by protonation of amino acids which can change the entire protein structure, or in some cases even denaturing the whole protein if pH is too low, completely preventing passage of molecules through the gap junctions.[7][8]

Functionality

edit

Gap junction enhancers (GJEs)

edit

Gap junction enhancers (GJEs) facilitate cell-to-cell communication by increasing gap junction coupling or inducing depolarization across cell membranes.[2][10] Examples include growth factors like TGF-beta and EGF, which are important in wound healing and tissue repair; retinoic acid, which plays a part in cellular differentiation; and acetylcholine (ACh), which contributes to learning, motivation, alertness, focus, and the stimulation of rapid eye movement (REM) sleep in the brain depolarizes the membrane potential closer to the threshold, thereby increasing the chance of neuron firing (the transfer of neurotransmitters).[2][27][28][29]

Gap junction inhibitors (GJIs)

edit

Gap junction inhibitors (GJIs) lessen communication between cells by lowering gap junction coupling or inducing hyperpolarization across cell membranes.[2][10] Among them are the anti-inflammatory and anti-tumor effects of 18-alpha-glycyrrhetinic acid (18-AGA); carbenoxolone, which are used to treat inflammatory diseases; and Gamma-aminobutyric acid (GABA), which blocks signals and lessens the likelihood to generate action potential through the hyperpolarization of neurons. These inhibitors play a significant part in regulating the hyperactivity of nerve cells linked to stress, anxiety, and terror.[30][31][32]

Connexin (Cx) specific modulators

edit

Connexin (Cx) specific modulators target the building blocks of gap junction channels - connexin proteins. For example, the Cx43 mimetic peptides Gap26 and Gap27 bind to extracellular loop regions one and two of CxHc (connexin hemichannels), respectively, to selectively block Cx43-based gap junctions, resulting in the rapid closure of these channels.[17][18][19][33]

Voltage-dependent modulators

edit

Voltage-dependent modulators modify the cell membrane potential, which has an impact on gap junctions.[8] For instance, substances like heptanol and quinine act as modulators and can interfere with gap junctions' ability to sense voltage, which inhibits the junctions.[9][34]

Natural compounds

edit

A variety of natural compounds such as flavonoids have been reported to modulate gap junction activity.[35][36] For example, it has been shown that the dietary flavonoid quercetin inhibits gap junction communication in specific cell types such as cardiovascular cells or cancer cells.[35][36]

Pharmaceutical agents

edit

It has been found that many drugs either work primarily by modulating gap junction function or produce unintended side effects.[10] Drugs that inhibit gap junction communication include the antiarrhythmic drug amiodarone, the anti-migraine drug tonabersat; or drugs that promote gap junction conduction, such as rotigaptide and danegaptide.[11][12][13]

Amiodarone

edit
 
Structural formula of Amiodarone.

Amiodarone treats ventricular arrhythmia, a potentially fatal form of arrhythmia, a disease of the heart where it has an irregular heartbeat that is either too fast or too slow.[11][37] It is especially recommended for patients who do not respond well to other typical therapies.[37] Amiodarone belongs to the third antiarrhythmic pharmacological class, which is known as antiarrhythmic drugs.[38] It helps to maintain a regular heart rhythm by acting directly on heart tissue and effectively slowing down nerve impulses to the heart.[11][38] In addition, amiodarone inhibits the potassium current, which repolarizes the myocardium during the third phase of the cardiac action potential.[11][38][39] As a result, the effective folding time of the heart cells and the length of the action potential are prolonged, which in turn reduces the incidence of arrhythmia.[39]

Tonabersat

edit
 
Structural formula of Tonabersat.

Tonabersat is a novel benzopyran compound that selectively binds to a unique brain site, α2δ-1 subunit of voltage-gated calcium channels.[4][12] This reduces calcium intake of this channel.[12][40] Calcium intake reduction of the channels is associated with reducing Cortical Spreading Depression (CSD) as it inhibits gap-junction communication.[10][12][41] This is important as CSD relies on neuronal-glial cell communication through connexin-containing gap junctions and hemichannels, and this abnormal sensory processing due to peripheral and/or central sensitization is found to cause migraines.[40][41]

Rotigaptide and danegaptide

edit

Recently, rotigaptide and danegaptide were found to be effective as an antidote to toxicity caused by overdose of certain drugs, such as Bupropion.[13][42][43] Bupropion is an antidepressant, but is also a cardiotoxin if ingested in large doses.[43] Rotigaptide and danegaptide, two small-molecule medications that increase gap junction conductance by facilitating gap junction activity, can prevent the binding or passing of bupropion to the cardiac gap junctions.[13][42][43] Thus the modulators can be essential to preventing overdose of bupropion.[42][43]

See also

edit

References

edit
  1. ^ a b c "Cell - Gap junctions". Encyclopedia Britannica. Retrieved 2024-03-16.
  2. ^ a b c d e f g h Salameh A, Dhein S. Pharmacology of gap junctions. new pharmacological targets for treatment of arrhythmia, seizure and cancer? Biochimica et Biophysica Acta (BBA) - Biomembranes. 2005;1719(1–2):36–58. doi:10.1016/j.bbamem.2005.09.007
  3. ^ a b c Noorman, Maartje; van der Heyden, Marcel A.G.; van Veen, Toon A.B.; Cox, Moniek G.P.J.; Hauer, Richard N.W.; de Bakker, Jacques M.T.; van Rijen, Harold V.M. (2009-04-01). "Cardiac cell–cell junctions in health and disease: Electrical versus mechanical coupling". Journal of Molecular and Cellular Cardiology. 47 (1): 23–31. doi:10.1016/j.yjmcc.2009.03.016.
  4. ^ a b c Rozental R, Giaume C, Spray DC. Gap junctions in the nervous system. Brain Research Reviews. 2000;32(1):11–15. doi:10.1016/s0165-0173(99)00095-8
  5. ^ a b Forge A, Becker D, Casalotti S, Edwards J, Evans WH, Lench N, Souter M. Gap junctions and connexin expression in the inner ear. Novartis Foundation Symposium
  6. ^ a b c d e f Kurtenbach S, Kurtenbach S, Zoidl G. Gap Junction modulation and its implications for heart function. Frontiers in Physiology. 2014;5. doi:10.3389/fphys.2014.00082
  7. ^ a b c d e f g Peracchia C. Chemical gating of Gap Junction channels. Biochimica et Biophysica Acta (BBA) - Biomembranes. 2004;1662(1–2):61–80. doi:10.1016/j.bbamem.2003.10.020
  8. ^ a b c d Palacios-Prado N, Briggs SW, Skeberdis VA, Pranevicius M, Bennett MV, Bukauskas FF. Ph-dependent modulation of voltage gating in Connexin45 homotypic and Connexin45/Connexin43 heterotypic gap junctions. Proceedings of the National Academy of Sciences. 2010;107(21):9897–9902. doi:10.1073/pnas.1004552107
  9. ^ a b Li G, Whittaker P, Yao M, Kloner RA, Przyklenk K. The gap junction uncoupler heptanol abrogates infarct size reduction with preconditioning in Mouse Hearts. Cardiovascular Pathology. 2002;11(3):158–165. doi:10.1016/s1054-8807(02)00102-3
  10. ^ a b c d e f g Shimizu K, Stopfer M. Gap Junctions. Current Biology. [accessed 2024 Mar 25]. https://www.cell.com/current-biology/pdf/S0960-9822(13)01342-0.pdf  219 ‐ Gap Junction‐Mediated Intercellular Signalling in Health and Disease. 2007 Sep 28:134–156. doi:10.1002/9780470515587.ch9
  11. ^ a b c d e Adesse D, Meirelles Azzam E, de Nazareth L. Meirelles M, Urbina JA, Garzoni LR. Amiodarone inhibits            trypanosoma cruzi            infection and promotes cardiac cell recovery with gap junction and cytoskeleton reassembly            in vitro. Antimicrobial Agents and Chemotherapy. 2011;55(1):203–210. doi:10.1128/aac.01129-10
  12. ^ a b c d e Silberstein S. Tonabersat, a novel gap-junction modulator for the prevention of Migraine. Cephalalgia. 2009;29(2_suppl):28–35. doi:10.1111/j.1468-2982.2009.01973.x
  13. ^ a b c d Kjølbye AL, Haugan K, Hennan JK, Petersen JS. Pharmacological modulation of Gap Junction function with the novel compound Rotigaptide: A promising new principle for prevention of arrhythmias. Basic & Clinical Pharmacology & Toxicology. 2007;101(4):215–230. doi:10.1111/j.1742-7843.2007.00123.x
  14. ^ a b Goodenough DA, Paul DL. Gap junctions. Cold Spring Harb Perspect Biol. 2009 Jul;1(1):a002576. doi: 10.1101/cshperspect.a002576. PMID 20066080; PMCID: PMC2742079
  15. ^ Sáez JC, Retamal MA, Basilio D, Bukauskas FF, Bennett MV. Connexin-based gap junction hemichannels: gating mechanisms. Biochim Biophys Acta. 2005 Jun 10;1711(2):215-24. doi: 10.1016/j.bbamem.2005.01.014. Epub 2005 Mar 2. PMID 15955306; PMCID: PMC3617572.
  16. ^ Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th edition. New York: Garland Science; 2002. Cell Junctions. Available from: https://www.ncbi.nlm.nih.gov/books/NBK26857/
  17. ^ a b c Lampe PD, Lau AF. The effects of connexin phosphorylation on gap junctional communication. The International Journal of Biochemistry & Cell Biology. 2004;36(7):1171–1186. doi:10.1016/s1357-2725(03)00264-4
  18. ^ a b c Cruciani V, Mikalsen S. Connexins, Gap Junctional intercellular communication and kinases. Biology of the Cell. 2002;94(7–8):433–443. doi:10.1016/s0248-4900(02)00014-x
  19. ^ a b c d Myers JB, Reichow SL. Structure of connexin-50 intercellular gap junction channel at 3.4 angstrom resolution by Cryoem. Protein Data Bank. 2018 Dec 12. doi:10.2210/pdb6mhy/pdb
  20. ^ a b Taylor SS, Wallbott M, Machal EM, Søberg K, Ahmed F, Bruystens J, Vu L, Baker B, Wu J, Raimondi F, et al. PKA CΒ: A forgotten catalytic subunit of camp-dependent protein kinase opens new windows for Pka Signaling and disease pathologies. Biochemical Journal. 2021;478(11):2101–2119. doi:10.1042/bcj20200867
  21. ^ Liu Z, Vogel HJ. NMR solution structure of the ca2+-calmodulin C-terminal domain in a complex with a peptide (NSCaTE) from the L-type voltage-gated calcium channel alpha1c subunit. Protein Data Bank. 2012 Jun 6. doi:10.2210/pdb2lqp/pdb
  22. ^ a b c d e Peracchia C. Calmodulin-mediated regulation of Gap Junction channels. International Journal of Molecular Sciences. 2020;21(2):485. doi:10.3390/ijms21020485
  23. ^ a b c d e Zhang M, Abrams C, Wang L, Gizzi A, He L, Lin R, Chen Y, Loll PJ, Pascal JM, Zhang J. Structural basis for calmodulin as a dynamic calcium sensor. Structure. 2012;20(5):911–923. doi:10.1016/j.str.2012.03.019
  24. ^ a b c Zou J, Salarian M, Chen Y, Veenstra R, Louis CF, Yang JJ. Gap Junction regulation by Calmodulin. FEBS Letters. 2014;588(8):1430–1438. doi:10.1016/j.febslet.2014.01.003
  25. ^ a b Lurtz MM, Louis CF. Calmodulin and protein kinase C regulate gap junctional coupling in lens epithelial cells. American Journal of Physiology. Cell Physiology. 2003;285(6). doi:10.1152/ajpcell.00361.2002
  26. ^ Ph scale. pH Scale | U.S. Geological Survey. [accessed 2024 Mar 27]. https://www.usgs.gov/media/images/ph-scale#:~:text=The%20pH%20scale%20measures%20how,a%20pH%20value%20of207.
  27. ^ Hirschi KK, Burt JM, Hirschi KD, Dai C. Gap Junction communication mediates transforming growth factor-β activation and endothelial-induced mural cell differentiation. Circulation Research. 2003;93(5):429–437. doi:10.1161/01.res.0000091259.84556.d5
  28. ^ Wu J, Taylor RN, Sidell N. Retinoic acid regulates gap junction intercellular communication in human endometrial stromal cells through modulation of the phosphorylation status of Connexin 43. Journal of Cellular Physiology. 2012;228(4):903–910. doi:10.1002/jcp.24241
  29. ^ professional CC medical. Acetylcholine (ACH): What it is, Function & Deficiency. Cleveland Clinic. 2024 [accessed 2024 Apr 10]. https://my.clevelandclinic.org/health/articles/24568-acetylcholine-ach
  30. ^ Takeda Y, Ward SM, Sanders KM, Koh SD. Effects of the gap junction blocker glycyrrhetinic acid on gastrointestinal smooth muscle cells. American Journal of Physiology. Gastrointestinal and Liver Physiology. 2005;288(4). doi:10.1152/ajpgi.00389.2004
  31. ^ Tamura K, Alessandri B, Heimann A, Kempski O. The effect of a gap-junction blocker, carbenoxolone, on ischemic brain injury and cortical spreading depression. Neuroscience. 2011;194:262–271. doi:10.1016/j.neuroscience.2011.07.043
  32. ^ professional CC medical. Gamma-aminobutyric acid (GABA): What it is, Function & Benefits. Cleveland Clinic. 2024 [accessed 2024 Apr 10]. https://my.clevelandclinic.org/health/articles/22857-gamma-aminobutyric-acid-gaba
  33. ^ Evans, William & Bultynck, Geert & Leybaert, Luc. (2012). Erratum to: Manipulating Connexin Communication Channels: Use of Peptidomimetics and the Translational Outputs. The Journal of membrane biology. 245. 437-49. 10.1007/s00232-012-9488-5.
  34. ^ Srinivas M, Hopperstad MG, Spray DC. Quinine blocks specific gap junction channel subtypes. Proceedings of the National Academy of Sciences. 2001;98(19):10942–10947. doi:10.1073/pnas.191206198
  35. ^ a b Lee DE, Shin BJ, Hur HJ, Kim JH, Kim J, Kang NJ, Kim DO, Lee CY, Lee KW, Lee HJ. Quercetin, the active phenolic component in kiwifruit, prevents hydrogen peroxide-induced inhibition of GAP-junction intercellular communication. British Journal of Nutrition. 2010;104(2):164–170. doi:10.1017/s0007114510000346
  36. ^ a b Yu B, Dong S, Yu M, Jiang G, Ji J, Tong X. Total flavonoids of Litsea coreana enhance the cytotoxicity of oxaliplatin by increasing gap junction intercellular communication. Biological and Pharmaceutical Bulletin. 2014;37(8):1315–1322. doi:10.1248/bpb.b14-00193
  37. ^ a b Amiodarone (oral route) description and brand names. Mayo Clinic. 2024 Apr 1 [accessed 2024 Apr 10]. https://www.mayoclinic.org/drugs-supplements/amiodarone-oral-route/description/drg-20061854#:~:text=Amiodarone%20is%20used%20to%20treat,that%20did%20not%20work%20well.
  38. ^ a b c Amiodarone. Uses, Interactions, Mechanism of Action | DrugBank Online. 2024 Apr 9 [accessed 2024 Apr 10]. https://go.drugbank.com/drugs/DB01118
  39. ^ a b Honjo H, Kodama I, Kamiya K, Toyama J: Block of cardiac sodium channels by amiodarone studied by using Vmax of action potential in single ventricular myocytes. Br J Pharmacol. 1991 Mar;102(3):651-6. doi: 10.1111/j.1476-5381.1991.tb12228.x.
  40. ^ a b Durham P, Garrett F. Neurological mechanisms of migraine: Potential of the gap-junction modulator tonabersat in prevention of Migraine. Cephalalgia. 2009;29(2_suppl):1–6. doi:10.1111/j.1468-2982.2009.01976.x
  41. ^ a b Smith JM, Bradley DP, James MF, Huang CL-H. Physiological studies of cortical spreading depression. Biological Reviews. 2006;81(04):457. doi:10.1017/s1464793106007081
  42. ^ a b c Bruss P, Hartle R, Astacio J, Chauhdri AF. Electrocardiographic effects of bupropion toxicity suggesting dysfunction of the gap junction or connexin 43. Cureus. 2024 Mar 16. doi:10.7759/cureus.56288
  43. ^ a b c d Losso L, Carollo M, Ricci G. Gap Junction modulators: Prospects in bupropion cardiotoxicity. Medical Hypotheses. 2024;185:111296. doi:10.1016/j.mehy.2024.111296
Retrieved from "https://en.wikipedia.org/w/index.php?title=Gap_junction_modulator&oldid=1252390726"